To include your compound in the COVID-19 Resource Center, submit it here.

Vertex seeks small molecules for RNA in deal with Ribometrix

In Vertex’s latest deal in its recent flurry of M&A activity, the big biotech has partnered with Ribometrix to discover and develop up to three RNA-targeted small molecule programs.

Founded in 2015, Durham, N.C.-based Ribometrix Inc. uses

Read the full 367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE